IMD-0560 |
Katalog-Nr.GC33306 |
IMD-0560 ist ein neuartiger IκB-Kinase-β-Inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 439144-66-8
Sample solution is provided at 25 µL, 10mM.
IMD-0560 is a novel IκB kinase β inhibitor.
Pretreatment with IMD-0560 inhibits both IκBα degradation and p65 phosphorylation induced by TNFα. IMD-0560 also suppresses TNFα-induced transcriptional activity. Pretreatment with IMD-0560 strongly inhibits TNFα-induced cell invasion. Pretreatment with IMD-0560 suppresses MMP-9 activity by inhibiting MMP-9 expression[1].
The tumor size is reduced in the IMD-0560-treated groups in a dose-dependent manner, and no tumor is detected in some mice treated with 5 mg/kg IMD-0560. Zygoma destruction is significantly suppressed in the IMD-0560-treated groups compare to the control groups. Although the tumor size in the 5 mg/kg IMD-0560-treated group is smaller than that of the 3 mg/kg IMD-0560-treated group, the inhibitory effect of each treatment on zygoma destruction is similar[1].
[1]. Tada Y, et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma. Oncotarget. 2014 Dec 15;5(23):12317-30.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *